Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
STAMPEDE2: Treatments for Metastatic Prostate Cancer
NCT06320067Phase 3Recruiting
- Sponsor
- University College London
- Start
- Jun 2024
- Primary completion
- Apr 2031
- Modality
- Small Molecules, Peptide-Drug Conjugates
- Countries
- 1
01
Overview
A Phase 3 trial of lutetium lu 177 vipivotide tetraxetan in prostate cancer (PCa), sponsored by University College London. Started Jun 2024; status: recruiting.
02
Drugs
lutetium lu 177 vipivotide tetraxetan
03
Conditions
prostate cancer (PCa)
Beyond the preview
Go deeper on NCT06320067.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06320067.